TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9952092

Group type: EXPERIMENTAL
Intervention: SGB (6 mL 1% lidocaine at C6)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Lidocaine (6 mL 1% lidocaine injected into subcutaneous tissue)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Saline (6 mL saline solution at C6)
Number of subjects: 24
Study: 7490909

Group type: COMPARATOR
Intervention: Iron supplementation for 8 weeks
Number of subjects: 371

Group type: COMPARATOR
Intervention: Iron treatment for 4 months
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: Training course for mothers on rearing environment for 21 days
Number of subjects: 371
Study: 2253528

Group type: EXPERIMENTAL
Intervention: 10 mg intravenous bolus dose of edrophonium
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 80 micrograms/kg intravenous bolus dose of edrophonium
Number of subjects: 150

Group type: COMPARATOR
Intervention: saline placebo injections
Number of subjects: 150
Study: 7406571

Group type: EXPERIMENTAL
Intervention: Cimetidine (300 mg every six hours)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Cimetidine (maximum dose)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Antacids (average requirement 41 cc/hour)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Cimetidine (initial treatment)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Antacids (supplementary dose)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Both treatments (cimetidine and antacids)
Number of subjects: 144
Study: 30411598

Group type: EXPERIMENTAL
Intervention: Tissue flossing intervention on one arm
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control (non-flossed arm)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Tissue flossing intervention
Number of subjects: 17
Study: 27920018

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 1,200 mg single dose
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 1,200 mg single dose (open-label post-trial study)
Number of subjects: 100
Study: 25697217

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) + oxaliplatin
Number of subjects: 32745

Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 32745

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU)
Number of subjects: 32745

Group type: EXPERIMENTAL
Intervention: Recurrence-free patients
Number of subjects: 32745

Group type: COMPARATOR
Intervention: Overall CC patients
Number of subjects: 32745
Study: 23703408

Group type: EXPERIMENTAL
Intervention: Transforaminal balloon treatment with a Fogarty balloon catheter (n = 32)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (transforaminal steroid injection without balloon treatment, n = 30)
Number of subjects: 62
Study: 19346411

Group type: EXPERIMENTAL
Intervention: Experimental group (fresh produce only)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (any groceries)
Number of subjects: 21
Study: 19125992

Group type: EXPERIMENTAL
Intervention: Alogliptin 12.5 mg
Number of subjects: 527

Group type: EXPERIMENTAL
Intervention: Alogliptin 25 mg
Number of subjects: 527

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 527
Study: 17431496

Group type: EXPERIMENTAL
Intervention: Dental amalgam restorations
Number of subjects: 534

Group type: COMPARATOR
Intervention: Mercury-free composite materials
Number of subjects: 534
Study: 14768776

Group type: EXPERIMENTAL
Intervention: Prestige IQ blood glucose monitoring device
Number of subjects: 61

Group type: COMPARATOR
Intervention: Other four commercially available blood glucose devices
Number of subjects: 61
Study: 11029841

Group type: EXPERIMENTAL
Intervention: Financial incentive
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control (no financial incentive)
Number of subjects: 200
Study: 8787880

Group type: EXPERIMENTAL
Intervention: 1 g every 8 h (q8h) bolus dosing (BD)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 1 g every 12 h (q12h) bolus dosing (BD)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 3 g over 24 h continuous infusion (CI)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 2 g over 24 h continuous infusion (CI)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Intermittent dosing (BD)
Number of subjects: 12
Study: 1465079

Group type: EXPERIMENTAL
Intervention: Protein restriction diet
Number of subjects: 456

Group type: EXPERIMENTAL
Intervention: Nephrosclerosis
Number of subjects: 456

Group type: EXPERIMENTAL
Intervention: Interstitial nephropathy
Number of subjects: 456

Group type: EXPERIMENTAL
Intervention: Glomerulonephritis
Number of subjects: 456

Group type: EXPERIMENTAL
Intervention: Polycystic kidney disease
Number of subjects: 456
Study: 6370151

Group type: EXPERIMENTAL
Intervention: Gradual penicillamine withdrawal
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Reintroduction of penicillamine
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Serological marker for predicting relapse
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Decreasing SH levels
Number of subjects: 38
Study: 3537288

Group type: EXPERIMENTAL
Intervention: Dimethicone-containing antacid gel (Asilone Gel)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Simple antacid gel
Number of subjects: 45
Study: 29417463

Group type: EXPERIMENTAL
Intervention: Fixed dose combination tablet of sofosbuvir and ledipasvir (400/90 mg)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: In vitro dissolution study
Number of subjects: 36
Study: 26654958

Group type: EXPERIMENTAL
Intervention: Empathic patient-centered approach (IG)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Standardized information on surgical procedures (CG)
Number of subjects: 104
Study: 25583761

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) with the everolimus-eluting stent
Number of subjects: 0

Group type: COMPARATOR
Intervention: Coronary artery bypass graft (CABG) surgery
Number of subjects: 0
Study: 24314158

Group type: EXPERIMENTAL
Intervention: Infliximab (IFX)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Enteral Nutrition (EN)
Number of subjects: 100
Study: 21271020

Group type: EXPERIMENTAL
Intervention: Phacoemulsification (PHACO)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Extracapsular extraction (EECP)
Number of subjects: 205
Study: 18649055

Group type: EXPERIMENTAL
Intervention: Atorvastatin (10 mg/day)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (no atorvastatin)
Number of subjects: 48
Study: 16628033

Group type: COMPARATOR
Intervention: Group A (2.0 mL/kg of 300 mgI/mL contrast medium, injection duration 30 seconds, mean rate 3.6 mL/sec)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Group B (2.0 mL/kg of 300 mgI/mL contrast medium, injection duration 25 seconds, mean rate 4.6 mL/sec)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Group C (2.0 mL/kg of 300 mgI/mL contrast medium, injection duration 30 seconds, mean rate 3.6 mL/sec followed by saline chaser)
Number of subjects: 60
Study: 14634681

Group type: EXPERIMENTAL
Intervention: Skill-based intervention (SBI)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Counseling-based intervention (CBI)
Number of subjects: 80
Study: 10825333

Group type: EXPERIMENTAL
Intervention: Ketamine 0.4 mg/kg IV before skin incision
Number of subjects: 89

Group type: COMPARATOR
Intervention: Saline 0.04 mL/kg IV immediately before and after surgery (Placebo)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Saline before skin incision, Ketamine 0.4 mg/kg IV after skin closure
Number of subjects: 89
Study: 8865508

Group type: EXPERIMENTAL
Intervention: Manually adjusted CPAP
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Self-titrating CPAP
Number of subjects: 20
Study: 1524140

Group type: EXPERIMENTAL
Intervention: Bovine immunoglobulin concentrate with high titer of anti-S. flexneri 2a LPS, administered three times a day for seven days.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control preparation with sodium bicarbonate, administered three times a day for seven days.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bovine immunoglobulin concentrate with high titer of anti-S. flexneri 2a LPS.
Number of subjects: 0
Study: 6470361

Group type: EXPERIMENTAL
Intervention: Ketotifen
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Clemastine
Number of subjects: 15
Study: 30675745

Group type: EXPERIMENTAL
Intervention: Flaminal® Forte
Number of subjects: 89

Group type: COMPARATOR
Intervention: Flamazine®
Number of subjects: 89
Study: 30302881

Group type: EXPERIMENTAL
Intervention: L-Dcau group (1 mL/kg of caudal 0.25% levobupivacaine plus 1 μg/kg dexmedetomidine and IV 20 mL saline)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: L-Div group (1 mL/kg of caudal 0.25% levobupivacaine and IV 1 μg/kg dexmedetomidine in 20 mL saline)
Number of subjects: 90

Group type: COMPARATOR
Intervention: L group (1 mL/kg of caudal 0.25% levobupivacaine and IV 20 mL saline)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: L-Dcau and L-Div groups
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 90
Study: 26883420

Group type: EXPERIMENTAL
Intervention: One-stage revision THR
Number of subjects: 148

Group type: COMPARATOR
Intervention: Two-stage revision THR
Number of subjects: 148
Study: 25032872

Group type: EXPERIMENTAL
Intervention: 13-valent conjugated vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 23-polysaccharide vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both vaccines (13-valent conjugated and 23-polysaccharide)
Number of subjects: 0
Study: 22864456

Group type: EXPERIMENTAL
Intervention: Systematic aortic and pelvic lymphadenectomy (SAPL)
Number of subjects: 308

Group type: COMPARATOR
Intervention: Resection of bulky nodes only (Control)
Number of subjects: 308
Study: 20160157

Group type: EXPERIMENTAL
Intervention: Linagliptin 1 mg
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Linagliptin 2.5 mg
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Linagliptin 5 mg
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Linagliptin 10 mg
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Linagliptin 2.5 mg (28 days)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Linagliptin 5 mg (28 days)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Linagliptin 10 mg (28 days)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Unbound linagliptin
Number of subjects: 2
Study: 17379591

Group type: EXPERIMENTAL
Intervention: Proton pump inhibitors (once or twice daily)
Number of subjects: 45
Study: 16583990

Group type: EXPERIMENTAL
Intervention: Standard Antibiotic Therapy (SAT) combined with amikacin
Number of subjects: 152

Group type: COMPARATOR
Intervention: Other Antibiotic Therapy (OAT) combined with amikacin
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Amikacin used in high once daily dose (HODD) with SAT or OAT
Number of subjects: 152

Group type: COMPARATOR
Intervention: Conventional Therapy (CT)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Amikacin HODD with TDM
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Amikacin HODD without TDM
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Direct costs of treatment with SAT
Number of subjects: 152

Group type: COMPARATOR
Intervention: Direct costs of treatment with OAT
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Hospitalization costs per patient
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Cost reduction by omitting TDM in patients without risk factors
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Overall cost reduction by introducing safe and cheap standard treatment
Number of subjects: 152
Study: 12131102

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 20

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 20
Study: 10819337

Group type: COMPARATOR
Intervention: DTaP + Hib + OPV
Number of subjects: 567

Group type: COMPARATOR
Intervention: DTaP/Hib + OPV
Number of subjects: 567

Group type: EXPERIMENTAL
Intervention: DTaP/Hib + IPV
Number of subjects: 567
Study: 8829420

Group type: EXPERIMENTAL
Intervention: Spinal block (T3-S5) prior to induction of anesthesia and surgery (Group A)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Spinal block performed after surgery prior to extubation of the trachea (Group B)
Number of subjects: 38
Study: 1535638

Group type: EXPERIMENTAL
Intervention: Assertiveness training (AT)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Waiting-list (WL) condition
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Role-play performance
Number of subjects: 34

Group type: COMPARATOR
Intervention: Social and recreational activities
Number of subjects: 34
Study: 2981789

Group type: EXPERIMENTAL
Intervention: Intervention not specified
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30343187

Group type: EXPERIMENTAL
Intervention: Brief interactive/motivational computerized intervention
Number of subjects: 58

Group type: COMPARATOR
Intervention: Static/educational computerized intervention
Number of subjects: 58
Study: 28746738

Group type: EXPERIMENTAL
Intervention: Health education programme focusing on developing emotional knowledge skills around daily health habits (eating, hygiene, sleep, and physical exercise) using game-based dynamics and an emotional diary.
Number of subjects: 30

Group type: COMPARATOR
Intervention: Usual school routine (Control group).
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Health education programme (experimental group).
Number of subjects: 30
Study: 27521377

Group type: EXPERIMENTAL
Intervention: Carer Supporter Programme (CSP)
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Group reminiscence therapy (RYCT)
Number of subjects: 291

Group type: COMPARATOR
Intervention: CSP and RYCT combined
Number of subjects: 291

Group type: COMPARATOR
Intervention: Usual care (TAU)
Number of subjects: 291

Group type: COMPARATOR
Intervention: CSP
Number of subjects: 291
Study: 24910935

Group type: EXPERIMENTAL
Intervention: Guidewire-assisted transpancreatic sphincterotomy (GATS)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Needle-knife sphincterotomy (NKS)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Both GATS and NKS
Number of subjects: 149
Study: 21975687

Group type: COMPARATOR
Intervention: 30% FiO2
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: 80% FiO2
Number of subjects: 72
Study: 20684665

Group type: EXPERIMENTAL
Intervention: DHEP heparin plaster
Number of subjects: 233

Group type: COMPARATOR
Intervention: Placebo plaster
Number of subjects: 233
Study: 18671909

Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (BTA) injection plus ankle‐foot casting (n=6)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Botulinum toxin A (BTA) alone (n=7)
Number of subjects: 13
Study: 15741721

Group type: EXPERIMENTAL
Intervention: Fluoride dentifrice
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo dentifrice
Number of subjects: 16
Study: 12567340

Group type: EXPERIMENTAL
Intervention: Femoral block with 20 mL 1% ropivacaine
Number of subjects: 80

Group type: COMPARATOR
Intervention: Intra-articular injection of 20 mL 1% ropivacaine
Number of subjects: 80
Study: 10080505

Group type: EXPERIMENTAL
Intervention: Human EEG reviewers
Number of subjects: 7

Group type: COMPARATOR
Intervention: Gotman automatic spike-detection system
Number of subjects: 7

Group type: COMPARATOR
Intervention: Wavelet detector
Number of subjects: 7

Group type: COMPARATOR
Intervention: Two-stage system
Number of subjects: 7
Study: 7769193

Group type: EXPERIMENTAL
Intervention: Misoprostol (200 micrograms q.i.d. for 13 doses) during indomethacin treatment (50 mg p.o. t.i.d. for 10 doses)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Indomethacin (50 mg p.o. t.i.d. for 10 doses)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Misoprostol treatment only
Number of subjects: 7
Study: 2320783

Group type: EXPERIMENTAL
Intervention: 5 mg of salbutamol delivered by a micronebulizer LSA on admission (HO)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 10 mg of additional salbutamol nebulised at H1 if less than 20% increase in PEF
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Theophylline or salbutamol intravenously given in a randomised fashion for Group II
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Combination of treatments at H8 for Group II in cases of failures
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Borg's scale dyspnoea level greater than 5 and peak flow less than 150 l/min
Number of subjects: 26
Study: 394754

Group type: EXPERIMENTAL
Intervention: Oral choline theophyllinate
Number of subjects: 14

Group type: COMPARATOR
Intervention: Beclomethasone dipropionate
Number of subjects: 14

Group type: COMPARATOR
Intervention: Reduction of the dose of beclomethasone from 400 microgram/day
Number of subjects: 14
Study: 31127718

Group type: EXPERIMENTAL
Intervention: Online recruitment
Number of subjects: 780

Group type: COMPARATOR
Intervention: General practice recruitment
Number of subjects: 780

Group type: COMPARATOR
Intervention: Other sources recruitment
Number of subjects: 780
Study: 28878436

Group type: EXPERIMENTAL
Intervention: Text message-based health literacy intervention
Number of subjects: 41

Group type: COMPARATOR
Intervention: Text message reminders (control)
Number of subjects: 41
Study: 25622149

Group type: EXPERIMENTAL
Intervention: B-Pa-Z
Number of subjects: 15

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: B-Z-C
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: B-Pa-Z-C
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: B-Pa-C
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Z alone
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: C alone
Number of subjects: 15
Study: 23256585

Group type: EXPERIMENTAL
Intervention: Active gas reduction (Group 1)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (Group 2)
Number of subjects: 200
Study: 21076311

Group type: EXPERIMENTAL
Intervention: Home-based exercise program (3 times a week for 8 weeks)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Home-based exercise program
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 32
Study: 19617879

Group type: EXPERIMENTAL
Intervention: 600 mg of pidolate Mg(2+) daily for 12 weeks
Number of subjects: 48

Group type: COMPARATOR
Intervention: Lifestyle recommendations only (Control)
Number of subjects: 48
Study: 17076751

Group type: EXPERIMENTAL
Intervention: Webster-Stratton Incredible Years video-based 14-week group programme
Number of subjects: 76
Study: 15570204

Group type: EXPERIMENTAL
Intervention: Hand-assisted laparoscopic surgery
Number of subjects: 60

Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 60
Study: 11697691

Group type: EXPERIMENTAL
Intervention: Local anaesthesia with epinephrine (1:80,000)
Number of subjects: 100
Study: 9388800

Group type: EXPERIMENTAL
Intervention: SNAP curriculum
Number of subjects: 242

Group type: COMPARATOR
Intervention: GN curriculum
Number of subjects: 242

Group type: COMPARATOR
Intervention: GN or SNAP curriculum
Number of subjects: 242
Study: 7974570

Group type: EXPERIMENTAL
Intervention: Aspirin 81 mg/day
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Ticlopidine 200 mg/day
Number of subjects: 238
Study: 2741218

Group type: EXPERIMENTAL
Intervention: CAP regimen (cyclophosphamide 200 mg/m2 i.v. days 1, 3 and 5, adriamycin 40 mg/m2 i.v. day 1, platinum 30 mg/m2 i.v. day 1, 3 and 5)
Number of subjects: 126

Group type: COMPARATOR
Intervention: FAC regimen (5‐FU 500 mg/m2 days 1 and 8, adriamycin 50 mg/m2 day 1, cyclophosphamide 500 mg/m2 day 1)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Comparison of CAP and FAC
Number of subjects: 126
Study: 239971

Group type: EXPERIMENTAL
Intervention: Subject control, graduated exposure, feedback
Number of subjects: 15

Group type: COMPARATOR
Intervention: Experimenter control, graduated exposure, feedback
Number of subjects: 15

Group type: COMPARATOR
Intervention: Experimenter control, nongraduated exposure, feedback
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 15
Study: 31216826

Group type: EXPERIMENTAL
Intervention: Adjuvant concurrent chemo-radiotherapy (more than 50 Gy dose)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Adjuvant concurrent chemo-radiotherapy (more than 5 weeks)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Adjuvant concurrent chemo-radiotherapy (1-4 weeks)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Adjuvant concurrent chemo-radiotherapy
Number of subjects: 125
Study: 28371298

Group type: EXPERIMENTAL
Intervention: TMD enriched with virgin olive oil (TMD-VOO, N = 71)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: TMD enriched with nuts (TMD-Nuts, N = 68)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Low-fat control diet (N = 71)
Number of subjects: 210
Study: 25988769

Group type: EXPERIMENTAL
Intervention: Polaprezinc (34 mg/day of zinc)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 70
Study: 22943577

Group type: EXPERIMENTAL
Intervention: Aripiprazole (15 mg/day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 21431424

Group type: EXPERIMENTAL
Intervention: Walking in forest environments
Number of subjects: 16

Group type: COMPARATOR
Intervention: Walking in urban area (control)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Walking exercise
Number of subjects: 16
Study: 19638966

Group type: EXPERIMENTAL
Intervention: Tandospirone citrate 10 mg t.i.d. for 4 weeks
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Tandospirone citrate
Number of subjects: 144

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study: 17598639

Group type: EXPERIMENTAL
Intervention: losartan (50 mg)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: valsartan (80 mg)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: eprosartan (600 mg)
Number of subjects: 82

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 82
Study: 15569038

Group type: EXPERIMENTAL
Intervention: Pimecrolimus cream 1%
Number of subjects: 961

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 961
Study: 11568071

Group type: EXPERIMENTAL
Intervention: Endovascular graft (EVG) treatment
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Open surgical repair (OSR) treatment
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 45
Study: 9990214

Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin 10 mg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin 5 mg
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control
Number of subjects: 32